• About
  • Meet The Team
  • Privacy Policy
Saturday, January 23, 2021

Stocks Telegraph
  • Login
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers
No Result
View All Result
Stocks Telegraph
No Result
View All Result

Should You Invest In Inovio Pharmaceuticals (NASDAQ: INO)?

by Hasnain R
September 17, 2020
in Featured
Share on FacebookShare on Twitter

Inovio Pharmaceuticals, Inc. (NASDAQ: INO), a biotechnology company has recorded an increase of 35.88% in its shares price as it has gained +4.89 on Wednesday. Inovio Pharmaceuticals has earlier participated in H.C. Wainwright 22nd Annual Global Investment Conference on September 14 where its CEO J. Joseph Kim has made two statements that excited its investors.

CEO J. Joseph disclosed that the Phase 1 study of its coronavirus vaccine candidate INO-4800 is currently in the peer review. He also revealed that the Inovio will soon announce the result of peer review in the coming weeks. Secondly, Inovio’s CEO said that the company is planning to start phase 2/3 testing for its investigational vaccine. The biotech company is waiting for the FDA approval for phase 2/3 which the company expects will happen soon. Inovio said that it is confident that it will receive the funding for the upcoming trials of the vaccine.

Inovio Pharmaceuticals is scheduled to participate in the upcoming two conferences including Cantor Global Healthcare Conference on September 17 and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit which will take place on September 23. Investors expected that the biotechnology company will announce the exciting news soon.

Inovio Pharmaceuticals (NASDAQ: INO) shares were trading up 35.88% at $18.52 at the time of writing on Thursday.  INO share price went from a low point around $1.91 to briefly over $33.79 in the past 52 weeks. It has moved up 867.10% from its 52-weeks low and moved down -45.19% from its 52-weeks low. If we look at its liquidity, it has a current ratio of 10.10. Inovio market cap has remained high, hitting $2.99 billion at the time of writing.

The company has earlier shared the result from the Phase 1 clinical trial of the coronavirus vaccine candidate but the industry investors were not satisfied with the result as the company didn’t give any details about immune responses in patients. But it is expected that the upcoming peer review could clear the doubts of industry observers.

Shares of Inovio Pharmaceuticals has experienced an unusual options activity on Wednesday trading session. The large volume is one option activity that is considered to be unusual. The volume of options activity means the number of shares contracts traded for a day. INO has experienced bullish sentiments which means to buy at/near ask price or a put is sold at/near bid price.

Previously, Inovio Pharmaceuticals has signed a contract with Thermo Fisher Scientific for the development of a coronavirus vaccine candidate, INO-4800. Inovio is planning to make the 100 million doses of INO-4800 by 2021 after receiving FDA approval.

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

Tags: Coronavirus VaccineFDAINOINO stockINO4800Inovio Pharmaceuticals Inc.Inovio Pharmaceuticals StockNASDAQ: INO

Related Posts

Featured

Top Cyclical Stocks to Watch For in 2021

January 23, 2021
Top Performers Markets Awaits News from Congress and the Federal Reserve
Featured

GameStop (GME) Stock Continues to Spike Days after the Appointment of Ryan Cohen

January 22, 2021
Top 3 Reasons Why AzurRx Biopharma Inc [AZRX] is Gaining Bullish Momentum
Featured

Fluidigm (FLDM) Stock Gives Green Signal as it obtains CE-IVD ‎Mark for Its COVID-19 Test

January 22, 2021
Tesla Inc (NASDAQ:TSLA) Stock Is Soaring. Here’s Why.
Featured

Jaguar Health (JAGX) Closes its $6M Promissory Notes, What’s Next for JAGX Stock?

January 21, 2021
Top 3 Big Data Stocks for long-term Investment
Featured

Top 3 Big Data Stocks for long-term Investment

January 21, 2021
TG Therapeutics (NASDAQ: TGTX) Ublituximab Receives Fast Track Designation In US
Featured

Adamis Pharmaceuticals Corp (ADMP) shares slide 14% as traders take profits

January 21, 2021
Next Post

Herman Miller (NASDAQ: MLHR) Announces First Quarter Fiscal 2021 Results

Looking for $1 Stock? BIOLASE (BIOL) is a Decent Bet

by Ali Hassan
January 21, 2021
0

The dental device firm is bullish and looks solid for long-term growth. The medical device firm, BIOLASE Inc. (BIOL) had...

Read more

Early Morning Vibes: The 4 Best Stocks To Buy Now

9 Trending Stocks in Travel Services Industry That Can Be A Good Bets
by Shan Zee
January 20, 2021
0

On January 19, American stock indexes finished trading in the green zone. The S&P 500 Index rose 0.81% to 3799...

Read more

Early Morning Vibes: Top 4 Stocks To Watch Right Now

Why Tesla Inc (NASDAQ: TSLA) Stock Might Be A Great Pick?
by Shan Zee
January 19, 2021
0

For Martin Luther King Day, the U.S. treasuries were closed yesterday. In the meantime, on Wednesday, the Americans are waiting...

Read more

Early Morning Vibes: 4 Stocks We Like for Thursday

Energy Focus (NASDAQ: EFOI) Introduces Portfolio Of Germicidal UV-C Disinfection Products
by Hasnain R
January 21, 2021
0

On January 20, American stock markets closed at new all-time highs. The S&P 500 index rose 1.39% to 3852 points,...

Read more

Early Morning Vibes: The 4 Best Stocks To Buy Now

Blonder Tongue Receives U.S. Patent Grant For DMM Series Of Products
by Shan Zee
January 14, 2021
0

American stock markets ended trading largely in the green zone on January 13. The S&P 500 index improved to 3810...

Read more
  • About
  • Meet The Team
  • Privacy Policy

© 2020 Stocks Telegraph - All Rights Reserved

No Result
View All Result
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers

© 2020 Stocks Telegraph - All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.